Nocturia

Sleep Disorders and Childhood Enuresis in Women with Overactive Bladder Syndrome: Cross-Sectional Study.

Childhood enuresis may be associated with overactive bladder syndrome (OAB) in adulthood, which may contribute to sleep disorders. The objective was to compare the prevalence of childhood enuresis and sleep quality among women with and without OAB.

Disruption of circadian rhythm as a potential pathogenesis of nocturia.

Increasing evidence suggested the multifactorial nature of nocturia, but the true pathogenesis of this condition still remains to be elucidated. Contemporary clinical medications are mostly symptom based, aimed at either reducing nocturnal urine volume or targeting autonomic receptors within the bladder to facilitate urine storage.

Retrospective Evaluation of the Efficacy of Electrophysiological Appropriate Techniques for Nocturia Following Radical Prostatectomy.

This study retrospectively examines the effectiveness of low-frequency electrical stimulation for addressing nocturia in patients experiencing urinary incontinence after undergoing radical prostatectomy.

Decadal changes in nocturia among American middle-aged and older men.

To estimate the prevalence of nocturia in middle-aged and elderly men and evaluate its associated factors and changes over time.

Data of middle-aged and older men aged ≥40 years from the 2007-2008 and 2017-2020 cycles of the National Health and Nutrition Examination Survey were retrospectively analyzed.

Characteristics of geriatric rehabilitation inpatients with nocturia: RESORT.

Nocturnal lower urinary tract symptoms (nLUTS) are common in geriatric rehabiliation inpatients but have not been well described. The aim of this study was to compare patient characteristics stratified by self-reported nocturia severity in geriatric rehabilitation inpatients.

History of clinical applications of desmopressin

Desmopressin is a synthetic analog of the endogenous peptide hormone arginine vasopressin, or antidiuretic hormone. The drug was initially developed in 1967 with the intention of creating a molecule that could treat central diabetes insipidus, a condition characterized by a deficiency of ADH and results in the production of large volumes of dilute urine (Zaoral et al., 1967). In the years since, therapeutic use of desmopressin has expanded beyond central diabetes insipidus to include the treatment of many other conditions, notably nocturnal polyuria in children with enuresis (bed wetting), adult nocturia, congenital bleeding disorders, and more. The purpose of the present narrative review is to recount the history of desmopressin, review its key therapeutic indications, and discuss important pharmacologic and pharmacokinetic considerations of this medication.

Lennox R. Ksido,a Cassandra V. Heaney,a Thomas F. Monaghan,b Jeffrey P. Weiss,a

  1. Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA
  2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Source: Lennox R. Ksido, Cassandra V. Heaney, Thomas F. Monaghan, Jeffrey P. Weiss, History of clinical applications of desmopressin. Continence. Volume 12, 2024, 101709, ISSN 2772-9737, https://doi.org/10.1016/j.cont.2024.101709.

A multisite feasibility study of integrated cognitive-behavioral treatment for co-existing nocturia and chronic insomnia.

Nocturia (waking from sleep at night to void) and chronic insomnia frequently co-exist in older adults, contributing synergistically to sleep disturbance. Treatments typically target either nocturia or insomnia rather than simultaneously addressing shared mechanisms for these disorders.

Prevalence of metabolic syndrome in adult patients with obstructive sleep apnea syndrome.

Obstructive sleep apnea syndrome (OSAS) is associated with cardiovascular risk factors that comprise metabolic syndrome, including central obesity, hypertension, insulin resistance, impaired glucose tolerance, and dyslipidaemia.

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP-STAR study.

Nocturia impairs the quality of life in patients with type 2 diabetes mellitus. Although sodium glucose co-transporter 2 inhibitors (SGLT2i) such as tofogliflozin increase urine volume, their impact on nocturia, in conjunction with dietary salt restriction, is less clear.

Cross-Cultural Adaptation and Psychometric Evaluation of the Brazilian Portuguese Version of the Nocturia Quality-of-Life Questionnaire.

The objective was to cross-culturally adapt and check for the reliability, internal consistency, and validity of the Nocturia Quality of Life Questionnaire (N-QoL) in Brazilian Portuguese (N-QoL-Br).